The impact of reimbursement criteria on the appropriateness of ‘statin’ prescribing
暂无分享,去创建一个
Erik Muls | Philippe Autier | Christian Brohet | C. Brohet | P. Autier | P. Mullie | E. Muls | N. Paquot | G. Vansant | J. Creplet | André-Robert Grivegnéee | Patrick Mullie | Jean Creplet | Greet Vansant | Nicolas Paquot | André-Robert Grivegnéee
[1] L. Prosser,et al. Cost-Effectiveness of Cholesterol-Lowering Therapies according to Selected Patient Characteristics , 2000, Annals of Internal Medicine.
[2] HOMAS,et al. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .
[3] G. Mancia,et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. , 1998, Atherosclerosis.
[4] G. Mancia,et al. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. , 1998, Blood pressure.
[5] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[6] P. Autier,et al. Coronary Heart Disease Risk Factors and LDL Cholesterol-Lowering Efficacy of Fibrates and Simvastatin , 1997 .
[7] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[8] E. Bruckert,et al. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia , 1995, Clinical cardiology.
[9] J. Larosa,et al. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.
[10] C. Hennekens,et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997, JAMA.
[11] P. Hebert. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997 .
[12] Peter W. Macfarlane,et al. Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia , 2004 .
[13] G. Guyatt,et al. Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. , 1998, Annals of internal medicine.
[14] Terje R Pedersen,et al. Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.
[15] J. Mckenney,et al. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.
[16] P. O S I T I O N S T A T E M E N T. Management of Dyslipidemia in Adults With Diabetes , 1998, Diabetes Care.
[17] F. Palace,et al. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries , 2001 .
[18] N. Santanello,et al. Cholesterol reduction yields clinical benefit: impact of statin trials. , 1998, Circulation.
[19] I. Durand-zaleski,et al. Assessment of the impact of fibrates and diet on survival and their cost-effectiveness: evidence from randomized, controlled trials in coronary heart disease and health economic evaluations. , 1999, Clinical therapeutics.
[20] T. Pearson,et al. The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patient. , 1997, The American journal of cardiology.
[21] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.